The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the importance of novel immunotherapies, including CAR-T cell therapy and bispecific antibodies, for the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Prof. Carlo-Stella then shares some results from a Phase I/II study evaluating glofitamab monotherapy in patients with R/R MCL (NCT03075696), commenting on the high response rates observed and the value of this agent in the MCL treatment landscape. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role ADC Therapeutics, Celgene/Bristol Myers Squibb, Karyopharm, Novartis, Sanofi, Roche, Merck Sharp & Dohme, Scenic Biotech
Honoraria: Merck Sharp & Dohme, Janssen Oncology, AstraZeneca, Celgene, Incyte, Gilead Sciences, Roche
